PubRank

John Zalcberg

Author PubWeight™ 56.06‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Delivering affordable cancer care in high-income countries. Lancet Oncol 2011 12.79
2 Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet 2004 11.37
3 Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis. Lancet Oncol 2007 6.82
4 KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. Eur J Cancer 2006 4.92
5 Randomized trial of short-course radiotherapy versus long-course chemoradiation comparing rates of local recurrence in patients with T3 rectal cancer: Trans-Tasman Radiation Oncology Group trial 01.04. J Clin Oncol 2012 4.91
6 NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST)--update of the NCCN clinical practice guidelines. J Natl Compr Canc Netw 2007 3.40
7 Palifermin reduces the incidence of oral mucositis in patients with metastatic colorectal cancer treated with fluorouracil-based chemotherapy. J Clin Oncol 2006 2.59
8 An expression-based site of origin diagnostic method designed for clinical application to cancer of unknown origin. Cancer Res 2005 1.52
9 Medical paternalism and expensive unsubsidised drugs. BMJ 2005 1.00
10 Signal therapy of breast cancers by the HDAC inhibitor FK228 that blocks the activation of PAK1 and abrogates the tamoxifen-resistance. Cancer Biol Ther 2005 0.93
11 Beyond 5-fluorouracil: new horizons in systemic therapy for advanced colorectal cancer. Expert Opin Investig Drugs 2005 0.87
12 Addition of gabapentin to a modified FOLFOX regimen does not reduce oxaliplatin-induced neurotoxicity. Clin Colorectal Cancer 2006 0.84
13 Regulation of MDR1 gene expression: emerging concepts. Drug Resist Updat 2000 0.83
14 Registry of gastric cancer treatment evaluation (REGATE): I baseline disease characteristics. Asia Pac J Clin Oncol 2013 0.80
15 Discussing expensive anticancer drugs. J Clin Oncol 2008 0.79
16 Single-agent irinotecan or FOLFIRI as second-line chemotherapy for advanced colorectal cancer; results of a randomised phase II study (DaVINCI) and meta-analysis [corrected]. Eur J Cancer 2011 0.78
17 Controversies in the management of gastrointestinal stromal tumors. Asia Pac J Clin Oncol 2014 0.77
18 Rectal cancer in Victoria in 1994: patterns of reported management. ANZ J Surg 2002 0.76
19 Applications of positron emission tomography in the development of molecular targeted cancer therapeutics. BioDrugs 2003 0.76
20 What constitutes a multidisciplinary team meeting? Asia Pac J Clin Oncol 2011 0.75
21 Is improving local control sufficient indication for radiotherapy in the management of rectal cancer? A response. ANZ J Surg 2003 0.75
22 Soft tissue metastasis of carcinoid tumour: a rare manifestation. ANZ J Surg 2004 0.75
23 Palliative chemotherapy: a clinical oxymoron. Lancet 2003 0.75
24 Registry of gastric cancer treatment evaluation (REGATE): II treatment practice. Asia Pac J Clin Oncol 2013 0.75
25 Recent developments in the systemic therapy of advanced gastroesophageal malignancies. Expert Opin Investig Drugs 2006 0.75
26 A novel combination of cisplatin, irinotecan, and capecitabine in patients with advanced cancer. Invest New Drugs 2004 0.75
27 Advances in Molecular Pathology and Treatment of Periampullary Cancers. Pancreas 2016 0.75
28 Modification of leucovorin dose within a simplified FOLFOX regimen improves tolerability without compromising efficacy. Clin Colorectal Cancer 2007 0.75